Select publications

Use of bisphosphonates in breast cancer

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37(18):2373-8. Abstract

Ali SM et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19(14):3434-7. Abstract

Berenson JR et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91(7):1191-200. Abstract

Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003;97(3 Suppl):859-65. Abstract

Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer 2002;10(5):399-407. Abstract

Brown JE, Coleman RE. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 2002;4(1):24-9. Abstract

Chlebowski RT. Factors influencing the role of bisphosphonates in breast cancer management. Semin Oncol 2001;28(4 Suppl 11):42-8. Abstract

Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of randomized phase III trials. Am J Clin Oncol 2002;25(6 Suppl 1):S25-31. Abstract

Coleman RE. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol 2001;28(4 Suppl 11):35-41. Abstract

Diel IJ. Prognostic factors for skeletal relapse in breast cancer. Cancer Treat Rev 2001;27(3):153- 7;discussion 159-64. Abstract

Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 2002:Abstract 12.

Gralow JR. The role of bisphosphonates as adjuvant therapy for breast cancer. Curr Oncol Rep 2001;3(6):506-15. Abstract

Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 2002;29(3 Suppl 11):134-44. Abstract

Jagdev SP et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001;84(8):1126-34. Abstract

Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97(3 Suppl):834-9. Abstract

Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003;97(3 Suppl):848-53. Abstract

Lipton A et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest 2002;20 Suppl 2:45-54. Abstract

Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25(6 Suppl 1):S10-8. Abstract

Michigami T et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002;75(3):249-58. Abstract

Mohla S et al. Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions. Cancer 2003;97(3 Suppl):719-25. Abstract

Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2(8):584-93. Abstract

Paterson AH. Bisphosphonates: Biological response modifiers in breast cancer. Clin Breast Cancer 2002;3(3):206-16; discussion 217-8. Abstract

Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002;(1):CD003474. Abstract

Perez EA. Metastatic bone disease in breast cancer: The patient's perspective. Semin Oncol 2001;28(4 Suppl 11):60-3. Abstract

Pickering LM, Mansi JL. The role of bisphosphonates in breast cancer management: Review article. Curr Med Res Opin 2002;18(5):284-95. Abstract

Plunkett TA, Rubens RD. Bisphosphonate therapy for patients with breast carcinoma. Cancer 2003;97(3 Suppl):854-8. Abstract

Powles T et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20(15):3219-24. Abstract

Reinholz GG et al. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: Identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat 2002;71(3):257- 68. Abstract

Saarto T et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19(1):10-7. Abstract

Saarto T et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001;20;84(8):1047-51. Abstract

Senaratne SG, Colston KW. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002;4(1):18-23. Abstract

Theriault RL, Hortobagyi GN. The evolving role of bisphosphonates. Semin Oncol 2001;28(3):284-90. Abstract

Tjalma WA et al. Reduction of visible bone metastases by clodronate therapy in breast cancer. Eur J Gynaecol Oncol 2001;22(3):215-6. Abstract

Van Poznak C. How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol 2001;28(4 Suppl 11):69-74. Abstract

Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control 2002;9(6):480-9. Abstract

Home · Search